{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:52Z","timestamp":1792596832320,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41591-024-03076-6","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:09:01Z","timestamp":1718604541000},"page":"2517-2527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2006","authenticated-orcid":false,"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4139-0618","authenticated-orcid":false,"given":"Ajit J.","family":"Nirmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-5890","authenticated-orcid":false,"given":"Jahan","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-3281","authenticated-orcid":false,"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3315-4538","authenticated-orcid":false,"given":"Esther","family":"Drill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bahgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Marzouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cathcart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-8584","authenticated-orcid":false,"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Khodadoust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-7357","authenticated-orcid":false,"given":"Nikita","family":"Kotlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Nikitina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-7764","authenticated-orcid":false,"given":"Olga","family":"Kudryashova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Zubareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Zornikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9910-4971","authenticated-orcid":false,"given":"Nara","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1541-9480","authenticated-orcid":false,"given":"Maria","family":"Sorokina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Degryse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3413-3122","authenticated-orcid":false,"given":"Ekaterina","family":"Postovalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Bagaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-1491","authenticated-orcid":false,"given":"Kinga","family":"Hosszu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"McAvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap J.","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Ciantra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson W.","family":"Appelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2112-1148","authenticated-orcid":false,"given":"Christopher","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Amaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-1298","authenticated-orcid":false,"given":"Santosha A.","family":"Vardhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"3076_CR1","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","volume":"108","author":"L Leseux","year":"2006","unstructured":"Leseux, L. et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108, 4156\u20134162 (2006).","journal-title":"Blood"},{"key":"3076_CR2","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius, M. et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108, 1668\u20131676 (2006).","journal-title":"Blood"},{"key":"3076_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2004-06-2125","volume":"105","author":"GZ Rassidakis","year":"2005","unstructured":"Rassidakis, G. Z. et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 105, 827\u2013829 (2005).","journal-title":"Blood"},{"key":"3076_CR4","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","volume":"108","author":"S Uddin","year":"2006","unstructured":"Uddin, S. et al. Role of phosphatidylinositol 3\u2032-kinase\/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108, 4178\u20134186 (2006).","journal-title":"Blood"},{"key":"3076_CR5","first-page":"2194","volume":"61","author":"A Slupianek","year":"2001","unstructured":"Slupianek, A. et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61, 2194\u20132199 (2001).","journal-title":"Cancer Res."},{"key":"3076_CR6","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2003-12-4290","volume":"105","author":"T Maeda","year":"2005","unstructured":"Maeda, T., Yagasaki, F., Ishikawa, M., Takahashi, N. & Bessho, M. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. Blood 105, 2115\u20132123 (2005).","journal-title":"Blood"},{"key":"3076_CR7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois, D. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128, 1490\u20131502 (2016).","journal-title":"Blood"},{"key":"3076_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bjh.14611","volume":"181","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Recurrent mutations in epigenetic modifiers and the PI3K\/AKT\/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. Br. J. Haematol. 181, 406\u2013410 (2018).","journal-title":"Br. J. Haematol."},{"key":"3076_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican, T. B. et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 133, 1664\u20131676 (2019).","journal-title":"Blood"},{"key":"3076_CR10","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani, Y. et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 33, 2867\u20132883 (2019).","journal-title":"Leukemia"},{"key":"3076_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","volume":"17","author":"Y Baohua","year":"2008","unstructured":"Baohua, Y., Xiaoyan, Z., Tiecheng, Z., Tao, Q. & Daren, S. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn. Mol. Pathol. 17, 159\u2013165 (2008).","journal-title":"Diagn. Mol. Pathol."},{"key":"3076_CR12","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1073\/pnas.1305656110","volume":"110","author":"M Pfeifer","year":"2013","unstructured":"Pfeifer, M. et al. PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 12420\u201312425 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3076_CR13","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/blood.V95.9.2937.009k15_2937_2942","volume":"95","author":"JJ Scarisbrick","year":"2000","unstructured":"Scarisbrick, J. J., Woolford, A. J., Russell-Jones, R. & Whittaker, S. J. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 95, 2937\u20132942 (2000).","journal-title":"Blood"},{"key":"3076_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4393","volume":"5","author":"S Nakahata","year":"2014","unstructured":"Nakahata, S. et al. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat. Commun. 5, 3393 (2014).","journal-title":"Nat. Commun."},{"key":"3076_CR15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","volume":"287","author":"T Sasaki","year":"2000","unstructured":"Sasaki, T. et al. Function of PI3K\u03b3 in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040\u20131046 (2000).","journal-title":"Science"},{"key":"3076_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"K Okkenhaug","year":"2002","unstructured":"Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110\u03b4 PI 3-kinase mutant mice. Science 297, 1031\u20131034 (2002).","journal-title":"Science"},{"key":"3076_CR17","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn, I. W. et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132, 2446\u20132455 (2018).","journal-title":"Blood"},{"key":"3076_CR18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn, I. W. et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J. Clin. Oncol. 37, 912\u2013922 (2019).","journal-title":"J. Clin. Oncol."},{"key":"3076_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling, M. et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann. Oncol. 28, 2169\u20132178 (2017).","journal-title":"Ann. Oncol."},{"key":"3076_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal, A. K. et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008\u20131018 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3076_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3076_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","volume":"23","author":"NC Richardson","year":"2022","unstructured":"Richardson, N. C., Kasamon, Y., Pazdur, R. & Gormley, N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 23, 563\u2013566 (2022).","journal-title":"Lancet Oncol."},{"key":"3076_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar, M. J. et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 678\u2013689 (2021).","journal-title":"Lancet Oncol."},{"key":"3076_CR24","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr, P. M. et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127, 2411\u20132415 (2016).","journal-title":"Blood"},{"key":"3076_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson, B. L. et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128, 195\u2013203 (2016).","journal-title":"Blood"},{"key":"3076_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","volume":"202","author":"S Chellappa","year":"2019","unstructured":"Chellappa, S. et al. The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. J. Immunol. 202, 1397\u20131405 (2019).","journal-title":"J. Immunol."},{"key":"3076_CR27","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo, E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019\u20135032 (2011).","journal-title":"Blood"},{"key":"3076_CR28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz, S. M. et al. Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131, 888\u2013898 (2018).","journal-title":"Blood"},{"key":"3076_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"3076_CR30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo, E. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140, 1229\u20131253 (2022).","journal-title":"Blood"},{"key":"3076_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","volume":"22","author":"H Ma","year":"2017","unstructured":"Ma, H. & Abdul-Hay, M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int. J. Clin. Oncol. 22, 18\u201351 (2017).","journal-title":"Int. J. Clin. Oncol."},{"key":"3076_CR32","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J. & Weisenburger, D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124\u20134130 (2008).","journal-title":"J. Clin. Oncol."},{"key":"3076_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei, M. et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 103, 1191\u20131197 (2018).","journal-title":"Haematologica"},{"key":"3076_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier, B. et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30, 631\u2013636 (2012).","journal-title":"J. Clin. Oncol."},{"key":"3076_CR35","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, O. A. et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J. Clin. Oncol. 33, 2492\u20132499 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3076_CR36","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz, S. M. et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123, 3095\u20133100 (2014).","journal-title":"Blood"},{"key":"3076_CR37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor, O. A. et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29, 1182\u20131189 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3076_CR38","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","volume":"20","author":"DG Winkler","year":"2013","unstructured":"Winkler, D. G. et al. PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364\u20131374 (2013).","journal-title":"Chem. Biol."},{"key":"3076_CR39","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","volume":"124","author":"S Dong","year":"2014","unstructured":"Dong, S. et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124, 3583\u20133586 (2014).","journal-title":"Blood"},{"key":"3076_CR40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"3076_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"3076_CR42","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1182\/blood-2019-121401","volume":"134","author":"SM Horwitz","year":"2019","unstructured":"Horwitz, S. M. et al. Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: selection of regimen for the dose-expansion phase. Blood 134, 1567\u20131567 (2019).","journal-title":"Blood"},{"key":"3076_CR43","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier, F. et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120, 1466\u20131469 (2012).","journal-title":"Blood"},{"key":"3076_CR44","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval, L. et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109, 4952\u20134963 (2007).","journal-title":"Blood"},{"key":"3076_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronne","year":"2012","unstructured":"Couronne, L., Bastard, C. & Bernard, O. A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95\u201396 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3076_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes, J. R. et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell 33, 259\u2013273 (2018).","journal-title":"Cancer Cell"},{"key":"3076_CR47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng, S. Y. et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood 132, 935\u2013947 (2018).","journal-title":"Blood"},{"key":"3076_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/21541248.2014.968004","volume":"5","author":"A Schaefer","year":"2014","unstructured":"Schaefer, A., Reinhard, N. R. & Hordijk, P. L. Toward understanding RhoGTPase specificity: structure, function and local activation. Small GTPases 5, 6 (2014).","journal-title":"Small GTPases"},{"key":"3076_CR49","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cell.2009.12.033","volume":"140","author":"B Yu","year":"2010","unstructured":"Yu, B. et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 140, 246\u2013256 (2010).","journal-title":"Cell"},{"key":"3076_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","volume":"156","author":"Y Xie","year":"2021","unstructured":"Xie, Y. & Jaffe, E. S. How I diagnose angioimmunoblastic T-cell lymphoma. Am. J. Clin. Pathol. 156, 1\u201314 (2021).","journal-title":"Am. J. Clin. Pathol."},{"key":"3076_CR51","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1084\/jem.179.4.1099","volume":"179","author":"Y Wakatsuki","year":"1994","unstructured":"Wakatsuki, Y., Neurath, M. F., Max, E. E. & Strober, W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J. Exp. Med. 179, 1099\u20131108 (1994).","journal-title":"J. Exp. Med."},{"key":"3076_CR52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.immuni.2008.06.001","volume":"29","author":"A Vogelzang","year":"2008","unstructured":"Vogelzang, A. et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29, 127\u2013137 (2008).","journal-title":"Immunity"},{"key":"3076_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.immuni.2008.05.009","volume":"29","author":"RI Nurieva","year":"2008","unstructured":"Nurieva, R. I. et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138\u2013149 (2008).","journal-title":"Immunity"},{"key":"3076_CR54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4049\/jimmunol.173.1.68","volume":"173","author":"T Chtanova","year":"2004","unstructured":"Chtanova, T. et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1\/Th2 effector cells that provide help for B cells. J. Immunol. 173, 68\u201378 (2004).","journal-title":"J. Immunol."},{"key":"3076_CR55","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1073\/pnas.0710140105","volume":"105","author":"S Ishii","year":"2008","unstructured":"Ishii, S., Kurasawa, Y., Wong, J. & Yu-Lee, L. Y. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc. Natl Acad. Sci. USA 105, 4179\u20134184 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3076_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbrc.2003.09.013","volume":"310","author":"EJ Noh","year":"2003","unstructured":"Noh, E. J. & Lee, J. S. Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2\u2013M transition. Biochem. Biophys. Res. Commun. 310, 267\u2013273 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3076_CR57","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","volume":"22","author":"A Britschgi","year":"2012","unstructured":"Britschgi, A. et al. JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22, 796\u2013811 (2012).","journal-title":"Cancer Cell"},{"key":"3076_CR58","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz, A. J. et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood 138, 2828\u20132837 (2021).","journal-title":"Blood"},{"key":"3076_CR59","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/j.1582-4934.2009.00787.x","volume":"13","author":"K Bourd-Boittin","year":"2009","unstructured":"Bourd-Boittin, K. et al. CX3CL1\/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J. Cell. Mol. Med. 13, 1526\u20131535 (2009).","journal-title":"J. Cell. Mol. Med."},{"key":"3076_CR60","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.23153","volume":"50","author":"X Shen","year":"2009","unstructured":"Shen, X. et al. CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia\/reperfusion injury. Hepatology 50, 1537\u20131546 (2009).","journal-title":"Hepatology"},{"key":"3076_CR61","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/hep.20432","volume":"40","author":"K Kimura","year":"2004","unstructured":"Kimura, K., Nagaki, M., Takai, S., Satake, S. & Moriwaki, H. Pivotal role of nuclear factor \u03baB signaling in anti-CD40-induced liver injury in mice. Hepatology 40, 1180\u20131189 (2004).","journal-title":"Hepatology"},{"key":"3076_CR62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hep.27087","volume":"60","author":"A Ikeda","year":"2014","unstructured":"Ikeda, A. et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology 60, 224\u2013236 (2014).","journal-title":"Hepatology"},{"key":"3076_CR63","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.4049\/jimmunol.159.8.3961","volume":"159","author":"H Tsutsui","year":"1997","unstructured":"Tsutsui, H. et al. IL-18 accounts for both TNF-\u03b1- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol. 159, 3961\u20133967 (1997).","journal-title":"J. Immunol."},{"key":"3076_CR64","first-page":"1904","volume":"46","author":"RT Ho","year":"1999","unstructured":"Ho, R. T., Liew, C. T. & Lai, K. N. The expression of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in damaged human liver and kidney tissues. Hepatogastroenterology 46, 1904\u20131909 (1999).","journal-title":"Hepatogastroenterology"},{"key":"3076_CR65","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00277-016-2597-y","volume":"95","author":"JC Jo","year":"2016","unstructured":"Jo, J. C. et al. Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Ann. Hematol. 95, 619\u2013624 (2016).","journal-title":"Ann. Hematol."},{"key":"3076_CR66","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta, N. et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin. Lymphoma Myeloma Leuk. 13, 664\u2013670 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"3076_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3076_CR68","doi-asserted-by":"publisher","first-page":"6882","DOI":"10.1158\/1078-0432.CCR-13-1906","volume":"19","author":"Y Oki","year":"2013","unstructured":"Oki, Y. et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin. Cancer Res. 19, 6882\u20136890 (2013).","journal-title":"Clin. Cancer Res."},{"key":"3076_CR69","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","volume":"126","author":"TE Witzig","year":"2015","unstructured":"Witzig, T. E. et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126, 328\u2013335 (2015).","journal-title":"Blood"},{"key":"3076_CR70","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"key":"3076_CR71","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2022.07.006","volume":"40","author":"A Zaitsev","year":"2022","unstructured":"Zaitsev, A. et al. Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. Cancer Cell 40, 879\u2013894 (2022).","journal-title":"Cancer Cell"},{"key":"3076_CR72","doi-asserted-by":"publisher","first-page":"e26476","DOI":"10.7554\/eLife.26476","volume":"6","author":"J Racle","year":"2017","unstructured":"Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E. & Gfeller, D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife 6, e26476 (2017).","journal-title":"eLife"},{"key":"3076_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04356-9","volume":"9","author":"SY Ng","year":"2018","unstructured":"Ng, S. Y. et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat. Commun. 9, 2024 (2018).","journal-title":"Nat. Commun."},{"key":"3076_CR74","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.cell.2020.10.037","volume":"183","author":"Y Su","year":"2020","unstructured":"Su, Y. et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell 183, 1479\u20131495 (2020).","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1038\/s41591-024-03404-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03076-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03076-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03076-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T03:03:17Z","timestamp":1731726197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03076-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3076"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03076-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03404-w","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03404-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M.W. is an employee of Merck and Co.; owns equity in Merck and Co., Bantam, Ajax and Travera; received consulting fees from AstraZeneca, Secura Bio, Novartis and Roche\/Genentech; and received research support from Daiichi Sankyo, AstraZeneca, Verastem, AbbVie, Novartis, Abcura and Surface Oncology. S.A.V. has served as an advisor for Immunai and has received consulting fees from ADC Therapeutics and Koch Disruptive Technologies. J.J.B. received consulting fees from Sobi, Omeros, Bluebird Bio, Sanofi, Immusoft, SmartImmune, Bluerock and Advanced Clinical. N.M.-S. has received institutional clinical trial funding from AstraZeneca, Bristol Myers Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech\/Roche, Innate Pharmaceuticals, Secura Bio\/Verastem, Yingli Pharmaceuticals and Dizal Pharmaceuticals. N.M.-S. has also received compensation for service as a consultant for AstraZeneca, Secura Bio\/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Janssen, Karyopharm Therapeutics and Kyowa Hakko Kirin. N.M.-S. is funded as a Scholar in Clinical Research through the Leukemia & Lymphoma Society, and this study was reviewed as part of the ASCO\/AACR Workshop. S.M.H. has received research support from ADC Therapeutics, Affimed, C4, Celgene, CRISPR Therapeutics, Daiichi Sankyo, Dren, Kyowa Hakko Kirin, Millennium\/Takeda, Seattle Genetics and Secura Bio. S.M.H. has also received consulting fees from Affimed, Abcuro, Corvus, Daiichi Sankyo, Kyowa Hakko Kirin, ONO Pharmaceuticals, SeaGen, Secura Bio, Takeda and Yingli Pharmaceuticals. A.J.M. has received research support from BeiGene, Seattle Genetics, Merck, Bristol Myers Squibb, Incyte, Affimed and AstraZeneca. A.J.M. has also received consulting fees from Affimed, Merck, Seattle Genetics and Takeda. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}